Silexion Therapeutics Corp
$1.08
▼
-2.42%
2026-04-21 09:29:00
silexion.com
NCM: SLXN
Explore Silexion Therapeutics Corp stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.63 M
Current Price
$1.08
52W High / Low
$22.36 / $0.97
Stock P/E
—
Book Value
$0.83
Dividend Yield
—
ROCE
-260.98%
ROE
1718.9%
Face Value
—
EPS
$-8.96
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13
Beta
0.06
Debt / Equity
78.22
Current Ratio
2.41
Quick Ratio
2.41
Forward P/E
-1.64
Price / Sales
—
Enterprise Value
$-0.46 M
EV / EBITDA
0.04
EV / Revenue
—
Rating
None
Target Price
$6
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lineage Cell Therapeutics, Inc. | $1.65 | — | $410.99 M | — | -21.52% | -1.05% | $2.09 / $0.4 | $0.18 |
| 2. | Metagenomi Therapeutics, Inc. | $1.53 | — | $55.68 M | — | -48.45% | -44.66% | $3.95 / $1.25 | $4.22 |
| 3. | Champions Oncology, Inc. | $6.08 | — | $84.36 M | — | 57.07% | -47.59% | $9.63 / $5.5 | $0.31 |
| 4. | Pasithea Therapeutics Corp. | $0.72 | — | $18.52 M | — | -37.74% | -58.36% | $3.79 / $0.28 | $2.39 |
| 5. | GeoVax Labs, Inc. | $1.17 | — | $3.38 M | — | -498.05% | -3.77% | $34.75 / $1.14 | $4.13 |
| 6. | Pharvaris N.V. | $28.97 | — | $1.86 B | — | -54.28% | -65.19% | $29.89 / $13.6 | $5.56 |
| 7. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -4.41 M | -3.29 M | -2.28 M | -1.65 M | -1.9 M | — |
| Net Profit | -4.41 M | -3.26 M | -2.5 M | -1.74 M | -1.75 M | — |
| EPS in Rs | -1.32 | -0.98 | -0.75 | -0.52 | -0.52 | -274.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -11.63 M | -12.57 M | -4.68 M | -3.86 M |
| Net Profit | -11.91 M | -16.44 M | -4.94 M | -3.21 M |
| EPS in Rs | -3.58 | -4.94 | -1.48 | -0.97 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 7.21 M | 2.86 M | 5.26 M | 9.33 M |
| Total Liabilities | 4.61 M | 6.85 M | 17.31 M | 16.41 M |
| Equity | 2.6 M | -3.99 M | -15.48 M | -10.66 M |
| Current Assets | 6.64 M | 2.25 M | 4.98 M | 8.84 M |
| Current Liabilities | 2.76 M | 3.52 M | 2.2 M | 1.61 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -10.82 M | -8.4 M | -4.53 M | -3.33 M |
| Investing CF | -0.01 M | -0.02 M | 0.57 M | -0.52 M |
| Financing CF | 15.64 M | 5.1 M | 0.52 M | 2.75 M |
| Free CF | -10.83 M | -8.42 M | -4.54 M | -3.38 M |
| Capex | -0.01 M | -0.02 M | -0.01 M | -0.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 27.56% | -232.72% | -53.72% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-07-29 | 1:0.0666667 |